Clinical study on CS-807 in respiratory tract infections

Abstract

CS-807 was studied clinically in respiratory tract infections: pneumonia 1, acute bronchitis 1, chronic bronchitis 2, secondary infection of pulmonary emphysema 1, socondary infection of bronchiectasis 1, and secondary infection of bronchial asthma 1. All patients were given 100–600mg CS-807 daily for 1–14 days. Clinical efficacy was evaluated as good in 4 cases, fair in 1, poor in 1, and unknown in 1. The clinical efficacy rate was 66.7%. Three patients given a unit dose of 400mg CS-807 were evaluated as showing good clinical effect. The clinical efficacy rate in lower respiratory tract infections was lower than in pneumonia and acute bronchitis. The bacteriological effect in five cases in whom the causative organisms were evaluated was: eradication in two cases, replacement in one, unchanged one and unknown one. As to side-effects, diarrhea was observed in one case. CS-807 was discontinued immediately, and after three days, the patient had recovered from diarrhea without treatment. No abnormal clinical tests were observed. These results suggest that CS-807 is a useful antibiotic in respiratory tract infections. © 1988, Japanese Society of Chemotherapy. All rights reserved.